... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Myeloproliferative neoplasms Hematologic malignancies Genetics Eosinophilia Polycythemia vera (PV...

...; Jianda Hu; Chunyan Chen; Xiequn Chen; Zhijian Xiao; Qian Jiang Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare...

...Omar A. Shahin; Helen T. Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek Background: Myeloproliferative neoplasms (MPNs) can transform into blast phase MPN (leukemic transformation; MPN-BP), typically via accelerated phase MPN (MPN-AP), in ∼20–25% of the cases. MPN-AP and MPN-BP...

...Odit Gutwein; Noa Lavi; Merav Barzilai; Adi Shacham-Abulafia; Avi Leader; Evgeni Chubar; Najib Dally; Shirley Shapira; Elena Mishchenko; Martin Ellis; Maya Koren-Michowitz The BCR-ABL-negative myeloproliferative neoplasms (MPN) are associated with high incidence of venous thrombosis...

...Selena Zhou; Douglas Tremblay; Ronald Hoffman; Marina Kremyanskaya; Vesna Najfeld; Lihua Li; Erin Moshier; John Mascarenhas Treatment options are limited for patients with advanced forms of myeloproliferative neoplasms (MPN) including blast-phase disease (MPN-BP). Decitabine has frequently been...

...Michael Asger Andersen; Ole Weis Bjerrum; Ajenthen Ranjan; Vibe Skov; Torben A. Kruse; Mads Thomassen; Axel Skytthe; Hans Carl Hasselbalch; Kaare Christensen Objective: Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterized by clonal hyperproliferation of immature...

... a partial response (PR) of cytopenias with immunosuppressive therapy. One patient achieved a PR following splenectomy. No patients were diagnosed with myeloproliferative neoplasms during the follow-up period. Conclusions: AIMF contributes to cytopenias in the subset of patients with various autoimmune...

..., allele burden and clinical significance, are scarce. We report the incidence and molecular characteristics of CALR mutations in a group of 184 Polish patients with myeloproliferative neoplasms (MPNs). Clinical data analysis revealed significant differences between JAK2 V617F-mutated and CALR -mutated...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Myeloproliferative neoplasms Essential thrombocythemia Polycythemia vera Aspirin Migraine-like cerebral and ocular ischemic attacks JAK2...

...Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Hendrik De Raeve The Polycythemia Vera Study Group (PVSG) and WHO classifications distinguished the Philadelphia (Ph 1 ) chromosome-positive chronic myeloid leukemia from the Ph 1 -negative myeloproliferative neoplasms (MPN) essential...

...E.M. Elli; A. Belotti; C. Cecchetti; S. Realini; M. Fedele; M. Parma; E.M. Pogliani The coexistence or the development of Philadelphia chromosome-negative myeloproliferative neoplasms after a lymphoproliferative disease in the same patient is an extremely rare event. We report the case of a 72-year...

...Caterina Musolino; Alessandro Allegra; Giuseppa Penna; Raffaella Centorrino; Maria Cuzzola; Arianna D’Angelo; Pasquale Iacopino; Andrea Alonci Background: Myeloproliferative neoplasms likely involve both myeloid and lymphoid lineages. Nevertheless, the coincidence of chronic myeloproliferative...